Table 4: Key eligibility criteria for reimbursement of ledipasvir-sofosbuvir reimbursement for treatment of hepatitis C virus infection, by jurisdiction

Jurisdiction	Restriction
Jurisdiction	Minimum fibrosis stage required	Substance use	HIV coinfection	Prescriber	Decompensated cirrhosis
Province/territory
British Columbia	F2	None listed*	Eligible	General practitioner	May be considered
Alberta	F2	None listed	Eligible	General practitioner	May be considered
Saskatchewan	F2	None listed†	Eligible	General practitioner	May be considered
Manitoba	F2	None listed	Eligible	Specialist	May be considered
Ontario	F2	None listed	Eligible	General practitioner	May be considered
Quebec	F3‡	None listed	Eligible§	General practitioner	Eligible
New Brunswick	F2	None listed	Eligible	General practitioner	None listed
Nova Scotia	F2	None listed	Eligible	Specialist	May be considered¶
Prince Edward Island	NA	NA	NA	NA	NA
Newfoundland and Labrador	F2	None listed	Eligible	General practitioner	May be considered
Yukon	F2	None listed	Eligible	Specialist	May be considered
Northwest Territories	F2	None listed	Eligible	General practitioner	None listed
Nunavut	F2	None listed	Eligible	General practitioner	None listed
Federal
Non-Insured Health Benefits Program	F2	None listed	Eligible	General practitioner	None listed
Correctional Service Canada	F2**	None listed††	Eligible	None listed	None listed

Note: NA = not available.

*No specific criteria, but exclusion criteria stated: "Patients who are at high risk for non-compliance."

†However, prescriber could indicate that directly observed therapy was recommended; also, the patient consented (via signature) to understanding treatment adherence.

‡In year 1 (2015/16), only those with stage F3 or F4 fibrosis received reimbursement.

§Treated in year 1 if stage F3 or F4 fibrosis.

¶Source: coauthor.

**Treatment prioritized to patients with stage F3 or F4 fibrosis; treatment for those with stage F0, F1 or F2 fibrosis was reviewed on a case-by-case basis.

††Directly observed therapy required.